Rheumatoid synovial fluid is characterized by an infiltrate of T cells that display markers of recent activation, while at the same time they are refractory to mitogenic stimulation. For example, the activation marker CD69 is constitutively expressed on the majority of SF T cells; however, stimulating the CD69 activation pathway does not induce cytokine production and cell proliferation. In addition, CD69, expressed on SF T cells, is capable of inducing TNF-alpha production from SF monocytes. This novel pathway leading to TNF-alpha production involves an unknown receptor on the surface of monocytes that is specific for CD69. Thus, on SF T cells CD69 appears to serve as a ligand that induces proinflammatory cytokine production by acting through a receptor on the surface of SF monocytes. An understanding of this new pathway may lead to novel approaches to inhibiting TNF production in rheumatoid synovium. The experiments in this proposal are designed to provide an understanding of the biochemical and molecular character of the CD69 receptor expressed on monocytic cells. These experiments will lead to a better understanding of the role of T cells in the initiation and progress of rheumatoid arthritis, and could lead to the identification of new biological targets for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Research Grants (R03)
Project #
5R03AR045770-03
Application #
6171191
Study Section
Special Emphasis Panel (ZAR1-JRL-A (O1))
Program Officer
Gretz, Elizabeth
Project Start
1998-09-30
Project End
2001-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
3
Fiscal Year
2000
Total Cost
$71,300
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
076647908
City
Seattle
State
WA
Country
United States
Zip Code
98101
Nakayama, Toshinori; Kasprowicz, Deborah J; Yamashita, Masakatsu et al. (2002) The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression. J Immunol 168:87-94